Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells. Here, the authors report the development and in vivo validation of a non-internalising ADC with the capacity to target cancer cells and release its therapeutic cargo extracellularly via a chemical trigger.
Guardado en:
Autores principales: | Raffaella Rossin, Ron M. Versteegen, Jeremy Wu, Alisher Khasanov, Hans J. Wessels, Erik J. Steenbergen, Wolter ten Hoeve, Henk M. Janssen, Arthur H. A. M. van Onzen, Peter J. Hudson, Marc S. Robillard |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b6e9e26c80024b1e84795b448f5f9b65 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
por: Raffaella Rossin, et al.
Publicado: (2019) -
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
por: Wenyan Fu, et al.
Publicado: (2019) -
Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells
por: Yinghua Zhao, et al.
Publicado: (2016) -
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
por: Rodrigo Vazquez-Lombardi, et al.
Publicado: (2017) -
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis
por: Christopher S. Lunde, et al.
Publicado: (2019)